Introduction
Cryptosporidium hominis is a water-borne protozoan parasite that infects the intestinal epithelium of many mammals, including humans. This highly infectious agent, recently placed on the Centers for Disease Control list of Class B bioterrorism agents, causes cryptosporidiosis, manifested as self-limiting diarrhea in immune-competent patients and massive chronic diarrhea in immune-de®cient patients (Guerrant, 1997; Tzipori, 1998) . Despite the threat of cryptosporidiosis infection, to date there are no clinically successful therapies.
Infections from closely related parasitic protozoa such as Plasmodium falciparum and Toxoplasma gondii have been treated with antifolates, inhibitors of dihydrofolate reductase (DHFR), an essential enzyme in the folate-biosynthetic pathway. DHFR catalyzes the reduction of dihydrofolate using NADPH as a cofactor. In protozoa, a single polypeptide chain codes for both DHFR and thymidylate synthase (TS), forming a bifunctional enzyme. Unfortunately, attempts to treat cryptosporidiosis with antifolates have been unsuccessful. The failure of these drugs has been observed both in vivo (Woods et al., 1996) and in vitro (Nelson & Rosowsky, 2001) . Vasquez et al. (1996) found that the sequence of C. hominis DHFR (ChDHFR) naturally contains Ile29, Thr58 and Cys113 at the same positions as the antifolate resistance-conferring mutations Ile51, Thr108 and Ile164 in P. falciparum DHFR (PfDHFR). The incorporation of these residues in ChDHFR was hypothesized to play an important role in in vitro antifolate resistance.
Since the sequence of DHFR has diverged and the sequence of TS has remained largely conserved throughout evolution, it is easier to design parasite-speci®c DHFR inhibitors instead of TS inhibitors. Therefore, in this work discussion will focus on the ChDHFR domain. In order to design selective and potent ChDHFR inhibitors in future studies, it is necessary to understand ligand binding in ChDHFR including (i) the interactions of the protein with ligands, (ii) the structural effects of the C. hominis residues predicted to play a role in antifolate resistance and (iii) ligand-induced conformational changes. Towards that goal, an analysis of two crystal structures of the enzyme DHFR-TS from C. hominis is presented. In one structure (structure I), presented in this manuscript, the enzyme is bound to an antifolate inhibitor, 1843U89 (OSI Pharmaceuticals), in the DHFR and TS active sites, as well as NADPH in the DHFR active site and the TS substrate deoxyuridine monophosphate (dUMP) in the TS active site. In the second structure (structure II), for which details regarding the crystallographic data and re®nement have previously been published, the enzyme is bound to the DHFR substrate dihydrofolate (DHF) and the cofactor NADPH in the DHFR active site and dUMP and an antifolate TS inhibitor, CB3717, in the TS active site. This structure formed the basis of previously reported research (O'Neil et al., 2003a,b) that established that there are two families of DHFR-TS structures from protozoa; analysis of the binding of DHF and NADPH will appear for the ®rst time in this work. A comparison of the structure of ChDHFR-TS with structures of the wild-type and the antifolate-resistant PfDHFR-TS (Yuvaniyama et al., 2003) shows that the ChDHFR residues hypothesized to be important in antifolate resistance have the same effects on the active site as the mutated P. falciparum residues known to be important in causing resistance, suggesting equivalent structural effects that decrease the af®nity of antifolates. Additionally, a comparison of the two ChDHFR-TS structures reveals no ligandinduced conformational changes in the DHFR active site. A comparison of ChDHFR-TS with human DHFR reveals sites in ChDHFR-TS that may be exploited for the design of parasiteselective inhibitors.
Materials and methods

DHFR activity assays
Enzyme puri®cation has been described previously (O'Neil et al., 2003a,b) . DHFR activity assays were performed using a solution of 50 mM TES buffer pH 7.0, 1 mM EDTA, 75 mM 2-mercaptoethanol, 1% bovine serum albumin, 1 mM dihydrofolate (Eprova) and 100 mM NADPH. Enzyme concentrations were adjusted to give linear initial velocities.
Crystallization and data collection
Pure enzyme was concentrated to 6.5 mg ml À1 and incubated with ligands on ice for 1 h. The ®nal concentrations of the ligands (note that all ligands were dissolved in water with the exception of TMP, which was dissolved in DMSO) were as follows: 1 mM TMP and 2 mM each of NADPH, dUMP and 1843U89 (OSI Pharmaceuticals). Crystals were grown by hanging-drop vapor diffusion at room temperature and appeared in drops where the reservoir solution contained 100 mM Tris pH 8.0, 11% PEG 6K, 50 mM ammonium sulfate and 0.2 M lithium sulfate. Crystals were transferred to a drop of arti®cial mother liquor containing 15% ethylene glycol and then transferred to a drop of arti®cial mother liquor containing 25% ethylene glycol before being frozen in liquid nitrogen. Diffraction data were collected at 100 K at Stanford Synchrotron Radiation Laboratory beamline 7-1. All data were indexed, integrated and scaled with the HKL package (Otwinowski, 1993) and converted to structure factors with TRUNCATE (Collaborative Computational Project, Number 4, 1994; see Table 1 for data statistics).
Structure solution
The structure of ChDHFR-TS bound to 1843U89, NADPH and dUMP was solved by difference Fourier techniques using structure II and re®ned using CNS (Bru È nger et al., 1998; Table 1 ). The R-factor and R free values, after simulated annealing and manually rebuilding residues surrounding the inhibitors, are 21.8 and 23.6%, respectively. The root-mean-square deviation of bonds is 0.008 A Ê and the r.m.s.d. for angles is 1.6 .
Results and discussion
Crystallographic structure determination
Structures I and II were solved with diffraction amplitudes extending to 2.87 and 2.8 A Ê , respectively. The resolution of these structures allows a determination of the proximity of hydrogen-bond donors and acceptors, but detailed measurements of hydrogen bonds will not be included. The determination of structure II has been described previously (O'Neil et al., 2003a,b; Lilien et al., 2004) ; structure I was solved using difference Fourier methods and phases from structure II. Electron density for the ligands and residues 3±521 protein structure communications
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is well de®ned (Fig. 1) . In the DHFR active site, omit map calculations clearly reveal electron density for 1843U89 in structure I and DHF in structure II, despite the fact that the protein±ligand crystallization mix included the known DHFR inhibitors trimethoprim and methotrexate, respectively. The presence of 1843U89 may be explained by results from a ChDHFR assay showing that 1843U89 exhibits a 50% inhibition (IC 50 ) value of 5 mM, threefold tighter binding than trimethoprim (IC 50 = 14 mM). The presence of DHF may be explained by the fact that the protein was immediately crystallized after 2 mM DHF elution from the methotrexate agarose column. ChDHFR-TS assembles as a dimer. In the asymmetric unit, one dimer is coincident with the crystallographic twofold axis and two dimers are located away from the axis, yielding ®ve monomers per asymmetric unit. The quality of the electron density in all ®ve monomers is essentially identical. The protein monomers were re®ned using non-crystallographic symmetry restraints.
Overall description of the DHFR-TS structure
ChDHFR-TS is a bifunctional protein organized with the N-terminal DHFR domain separated from the C-terminal TS domain by a 59-residue linker domain (Fig. 2) . After folding the DHFR domain (1±175), residues from the linker domain (176±206) cross from one monomer of the dimer to the other and form a helix, called the donated helix, which packs against the opposite DHFR active site. The interactions of the donated helix with the opposite monomer have been described in detail in a previous publication (O 'Neil et al., 2003a,b) . The linker then crosses back to the originating monomer, forming a ninth strand in the -sheet of DHFR, and then forms the TS domain (residues 207±521; O' Neil et al., 2003a,b) . In the crystal structures described here, ChDHFR has features that de®ne the closed conformation of P. carinii DHFR (PcDHFR; Cody et al., 1999) , suggesting that ChDHFR is in the closed conformation.
Ligand binding in ChDHFR-TS
NADPH is bound to ChDHFR in an extended conformation (Figs. 3a and 3b ). There are several hydrophobic interactions between NADPH and ChDHFR, including Ile75 and Ile118 with the adenosine, and Leu25, Ile19, Thr58, Tyr119, Gly115 and the pteridine ring of dihydrofolate or the benzoquinazoline ring of 1843U89 with the nicotinamide ring. Several potential hydrogen bonds are also apparent: Ser76, Ser77 and Arg56 with the O atoms of the adenosyl phosphate, Thr58 and Ser117 with the O atoms of the bridge phosphate and the backbone of Ala11 with the amino and keto oxygen groups of the nicotinamide ring. The antifolate 1843U89 (OSI Pharmaceuticals), originally developed as an anticancer TS inhibitor, is bound in the DHFR active site of structure I (Fig. 3a) . One hydrogen bond is formed from the benzoquinazoline ring to Asp32 and the methyl group on that ring is buried in a small hydrophobic pocket comprised of Thr134, Ala11 and Val9. Phe36, Leu25 and Ile62 form other hydrophobic contacts with the benzoquinazoline ring. The isoindolinone moiety is bound in a highly hydrophobic pocket comprised of Leu67, Ile62, Met54, Leu33, Phe36 and Leu25. The folate tail makes two potential hydrogen bonds with Arg70 and one with an ordered water molecule.
Interestingly, 1843U89 is bound in both the DHFR and TS active sites of structure I. It is noteworthy that both sites include a predominance of hydrophobic interactions. In fact, there are no potential hydrogen bonds between 1843U89 and C. hominis TS and only four in ChDHFR, despite the number of hydrogen-bond donors and acceptors in 1843U89.
Dihydrofolate is bound to ChDHFR in the same conformation as in the human enzyme (PDB code 1drf; Oefner et al., 1988; Fig. 3b ). The pteridine ring forms three hydrogen bonds with the protein: one from the amino group to Thr134, another from the ring NH to the carboxylate of Asp32 and a third from the amino group to Asp32. The pteridine ring also has extensive van der Waals contacts with Phe36, Val9 and the nicotinamide ring. The para-aminobenzoic acid (pABA) binds in the same location as the isoindolinone ring of 1843U89 and makes many of the same hydrophobic interactions with the protein.
There are three potential hydrogen bonds formed between the glutamate tail of dihydrofolate and the protein: two bonds with Arg70 and a unique hydrogen bond relative to other species with the side chain of Ser37.
Structural effects of residues predicted to be important in antifolate resistance
Using a comparison of the structures of wild-type and resistant PfDHFR-TS, Yuvaniyama and coworkers determined many of the structural effects of the PfDHFR mutations known to cause antifolate resistance (Yuvaniyama et al., 2003) . Vasquez et al. (1996) used a sequence alignment (Fig. 4) to show that residues Ile29, Thr58 and Cys113 are at the same positions as the mutations Ile51, Asn108 and Leu164 in resistant PfDHFR. A comparison of ChDHFR with the structures of wild-type PfDHFR and the quadruple mutant (Asn51Ile, Cys59Arg, Ser108Asn, Ile164Leu) PfDHFR (Yuvaniyama et al., 2003) (Fig. 5 ) reveals that ChDHFR residues Ile29, Thr58 and Cys113 have equivalent structural perturbations on the active site.
Wild-type PfDHFR contains Asn51, which forms a hydrogen bond with the backbone amide of the active-site Asn, which in turn forms hydrogen bonds with the diaminopyrimidine of most antifolate inhibitors. Ile29 (ChDHFR) and the resistance mutation Ile51 (PfDHFR) superimpose; both lose the hydrogen bond with the active-site Asn, creating a backbone shift at the active site. Thr58 in ChDHFR superimposes with the PfDHFR mutation Asn108. Asn108 creates steric interactions with the nicotinamide ring of NADPH and the para-chlorophenyl group of pyrimethamine (Yuvaniyama et al., 2003) . The same interactions are apparent for Thr58 in ChDHFR. Finally, in PfDHFR the Ile164Leu mutation causes an additional sevenfold reduction in binding to pyrimethamine (Sirawaraporn et al., 1997) , presumably owing to reduced van der Waals contacts. In ChDHFR, Cys113 exhibits an even greater reduction in van der Waals contacts (Fig. 5) , possibly severely decreasing antifolate af®-nity.
Evidence from ®eld isolates (Basco et al., 1996) and in vitro experiments (Sirawaraporn et al., 1997) shows that the appearance of multiple mutations in resistant strains of Plasmodium has a synergistic effect in decreasing the af®nity of antifolate inhibitors. For example, the Ser108Thr mutation by itself does not lead to a high degree of resistance, but this mutation in combination with Ala16Thr leads to high levels of cycloguanil resistance (Foote et al., 1990; Peterson et al., 1990) . The same argument may apply to C. hominis: a single residue may not contribute more than a slight increase in the binding constant of an inhibitor, but the accumulation of multiple residues may cause a signi®cant loss of af®nity. In ChDHFR, the decreased van der Waals surface of Cys113, the steric interactions of Thr58 and the loss of a key hydrogen bond from Ile29 may together lead to a pronounced decrease in antifolate binding.
Ligand-induced conformational changes
A comparison of ChDHFR bound to DHF and 1843U89 surprisingly reveals that there are few conformational changes in the protein induced by the differences between DHF and 1843U89. The benzoquinazoline ring of 1843U89 ®ts into the same space as the CH 2 N bridge of DHF. The isoindolinone appears to be accommodated in a greater volume of the hydrophobic pocket and forms contacts with Ile62, Leu67, Leu33 and Phe36. In comparison, the pABA ring of DHF contacts the same residues, with the exception of Leu67.
Selectivity: comparison with human DHFR
A superposition of the structures of ChDHFR with DHFR from human (PDB code 1drf; Oefner et al., 1988) , P. carinii (PDB code 2cd2; Cody et al., 1999) and Escherichia coli (PDB code 1rb3; Sawaya & Kraut, 1997) shows strong conservation of the overall conformation of DHFR, but also reveals a signi®cant difference between ChDHFR, PcDHFR and human DHFR. Human DHFR has a loop (residues 63±65 and sequence Pro-Glu-Lys-Asn, PEKN) near the exit to the active site; this loop is deleted in ChDHFR (Figs. 4 and 6) . The conformation of the PEKN loop and the initial proline residue is conserved in most other eukaryotic DHFR species. The proline in the human DHFR structure (Oefner et al., 1988) Figure 4 Sequence alignment of the DHFR domains from C. hominis (Ch), human (Hu) and P. falciparum (Pf; wild type). The PEKN region is shown in a green box; the residues involved in antifolate resistance in P. falciparum and C. hominis are shown in red.
Figure 5
Stereoview of a superposition of DHF from structure II of ChDHFR (green) and three residues from ChDHFR predicted to be important in causing antifolate resistance (Ile29, Thr58 and Cys113 in green) with residues from wild-type PfDHFR (red), the inhibitor WR99210 (red) and resistant PfDHFR (blue).
human DHFR. The valine substitution has reduced van der Waals contact with the pteridine ring in structure II. The substitution of Leu33 relative to Phe31 in the human enzyme has been implicated in the selectivity of trimethoprim for parasitic and bacterial species over human (Kuyper et al., 1985; Roth et al., 1987) .
In summary, the two structures of ChDHFR-TS reveal the interactions of residues in the DHFR domain with different ligands, show that the structural effects of the residues implicated in antifolate resistance are similar to the structural effects of the mutations found in resistant strains of P. falciparum and also reveal key structural differences with human DHFR. The information discovered here will be valuable in the design of potent and selective ChDHFR inhibitors.
